MedTrace Logo

N-methyl Glycine (Sarcosine) for the Treatment of Obsessive Compulsive Disorder (OCD)

NCT01031927 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2009-12-29

No results posted yet for this study

Summary

Several lines of evidence implicate glutamatergic dysfunction in the pathophysiology of obsessive compulsive disorder (OCD). Sarcosine, also known as N-methylglycine, is an endogenous antagonist of glycine transporter-I (GlyT-I), which potentiates glycine's action at the glycine site of N-methyl-D-aspartate (NMDA) receptors. In this 10-week open-label trial, we examined the efficacy and safety of sarcosine treatment in OCD patients.

Conditions

  • Obsessive Compulsive Disorder

Interventions

DRUG

N-methyl glycine

staring from 500mg/day, increased by 500mg biweekly, up to maximin of 2000mg/day

Sponsors & Collaborators

  • Taipei City Hospital

    collaborator OTHER_GOV

  • China Medical University Hospital

    lead OTHER

Principal Investigators

  • Guochuan E Tsai, MD, PhD · Department of Psychiatry, Harbor-UCLA Medical Center, California, U.S.A

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2009-02-28

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01031927 on ClinicalTrials.gov